7 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase and Sale of Shares and PDMR Shareholdings

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces the following Director and PDMR share dealings.

On 5 April 2022, Nick Roberts, CFO of Diaceutics, purchased 39,179 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.015 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 39,179 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital.

On 6 April 2022, Deborah Davis, the Chair of Diaceutics, purchased 20,000 Ordinary Shares at an average price of £1.0125 pence per share. As a result of the purchase, Deborah's shareholding is 64,800 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

On 6 April 2022, Charles Hindson, Non-Executive Director of Diaceutics, purchased 20,000 Ordinary Shares at a price of £1.01 pence per share. As a result of the purchase, Charles' shareholding is 63,500 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

Across 5 and 6 April 2022, Philip White, a PDMR, sold 200,000 Ordinary Shares at an average price of £0.989 pence per Ordinary Share. As a result of Philip's sale, the beneficial holding of Philip White and his connected parties in the Company is 1,406,389 Ordinary Shares, representing 1.67 % of the Company's issued share capital.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.